Deccan Health Care (BOM:542248) ROCE %: 1.78% (As of Mar. 2026)


BOM:542248 Deccan Health Care Ltd BOM:542248
81 GF Score
Price ₹13.43
GF Value ₹26.20
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Deccan Health Care ROCE %?

Deccan Health Care BOM:542248 -1.97% 81 ROCE % is 1.78% as of Mar. 2026. GuruFocus rates BOM:542248 with a GF Score™ of 81/100 and a GF Value™ of ₹26.20 (Significantly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Deccan Health Care's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.78%.

Deccan Health Care  (BOM:542248) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Deccan Health Care ROCE % Related Terms

Deccan Health Care ROCE % Historical Data

* Premium members only.

The historical data trend for Deccan Health Care's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Deccan Health Care ROCE % Chart

Deccan Health Care Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.64 2.45 1.62 3.24

Deccan Health Care Quarterly Data
Sep20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 1.29 4.95 4.92 1.78
BOM:542248
81GF Score
Deccan Health Care Ltd BOM:542248
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Deccan Health Care ROCE % Calculation

Deccan Health Care's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=36.32/( ( (1249.271 - 156.97) + (1489.089 - 340.474) )/ 2 )
=36.32/( (1092.301+1148.615)/ 2 )
=36.32/1120.458
=3.24 %

Deccan Health Care's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=20.412/( ( (0 - 0) + (1489.089 - 340.474) )/ 1 )
=20.412/( ( 0 + 1148.615 )/ 1 )
=20.412/1148.615
=1.78 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.78% mean?
Deccan Health Care (BOM:542248) has a ROCE % of 1.78% as of Mar. 2026.
Is Deccan Health Care's ROCE % too high?
Deccan Health Care's current ROCE % is 1.78%. The Drug Manufacturers industry median ROCE % is 7.03. Deccan Health Care's value of 1.78% is 74.7% below this industry median. Overall, Deccan Health Care has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Deccan Health Care's ROCE % compare to ZTS and UTHR?
Deccan Health Care's ROCE % of 1.78% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Deccan Health Care's value of 1.78% is 74.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Deccan Health Care's current ROCE % of 1.78% is 74.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Deccan Health Care's current ROCE % is 1.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Deccan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Deccan Health Care (BOM:542248) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹26.20, compared to a current price of ₹13.43 — trading 48.7% below its estimated fair value. The current ROCE % is 1.78% and 74.7% below the Drug Manufacturers industry median of 7.03. Deccan Health Care's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Deccan Health Care (BOM:542248), the current ROCE % is 1.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Deccan Health Care (BOM:542248) Overvalued in 2026?

Based on GuruFocus' analysis, Deccan Health Care stock appears to be undervalued. The current stock price of ₹13.43 is trading 48.7% below its estimated GF Value™ of ₹26.20. GuruFocus considers Deccan Health Care to be Significantly Undervalued.

Key valuation signals for BOM:542248:

  • ROCE %: 1.78%
  • GF Value™: ₹26.20 vs. price of ₹13.43 (48.7% below fair value)
  • GF Score™: 81/100 with 6 warning signs
  • Industry Position: 74.7% below the Drug Manufacturers median

No single metric tells the full story. See the BOM:542248 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Deccan Health Care Business Description

Address 6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Punjagutta, Hyderabad, TG, IND, 500082
Deccan Health Care Ltd is into developing, manufacturing, and marketing a broad range of healthcare products, including nutraceutical, cosmeceutical, and ayurveda products (Fast Moving Consumer Health Products). Its products are Nutraceutical Food Products and other supplements and medicines. The company is operating in a single segment of manufacturing of nutraceutical products. The company operates in India as well as exports its products to other countries, and the majority of its revenue comes from India.
81GF Score

Get the complete analysis for BOM:542248

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹13.43
Price
₹26.20
GF Value